Article

Laser has CE mark approval

Upon receiving CE mark approval to market in Europe, OptiMedica Corp. expects to begin shipping its laser system for cataract surgery (Catalys Precision) in the fourth quarter of this year.

Santa Clara, CA-Upon receiving CE mark approval for marketing in Europe, OptiMedica Corp. expects to begin shipping its laser system for cataract surgery (Catalys Precision) in the fourth quarter of this year.

The system is CE mark-approved to deliver capsulotomy and lens fragmentation. The company expects the system to receive CE mark approval for corneal incisions soon.

It combines a femtosecond laser, integrated optical coherence tomography imaging, and the company’s pattern scanning technology. The system is designed to be ergonomic and easy to use to improve the precision and accuracy of cataract surgery.

Key innovations, according to the company, include an interface designed to ensure stable system-patient attachment and to optimize the optical path to the patient’s eye, a proprietary guidance system designed to ensure that the femtosecond laser pulses are delivered safely and precisely to the intended location, and a graphical user interface created to simplify the planning process and to minimize the time that the patient is under the dock.

“We believe that the field of cataract surgery is in the midst of a revolutionary change, and we expect [the system] to provide leading technology that satisfies the high expectations of surgeons and their patients,” said Mark J. Forchette, OptiMedica president and chief executive officer. The company expects to introduce the system to markets around the world soon, he added.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.